Cargando…
Allogeneic transplant procurement in the times of COVID-19: Quality report from the central European cryopreservation site
BACKGROUND: Because of limitations of transportation imposed by the COVID-19 pandemic, current recommendation calls for cryopreservation of allogeneic stem cell transplants before patient conditioning. A single cell therapy laboratory was selected to function as the central cryopreservation hub for...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8027980/ https://www.ncbi.nlm.nih.gov/pubmed/33832504 http://dx.doi.org/10.1186/s12967-021-02810-9 |
_version_ | 1783675899880669184 |
---|---|
author | Wiercinska, Eliza Schlipfenbacher, Vera Bug, Gesine Bader, Peter Verbeek, Mareike Seifried, Erhard Bonig, Halvard |
author_facet | Wiercinska, Eliza Schlipfenbacher, Vera Bug, Gesine Bader, Peter Verbeek, Mareike Seifried, Erhard Bonig, Halvard |
author_sort | Wiercinska, Eliza |
collection | PubMed |
description | BACKGROUND: Because of limitations of transportation imposed by the COVID-19 pandemic, current recommendation calls for cryopreservation of allogeneic stem cell transplants before patient conditioning. A single cell therapy laboratory was selected to function as the central cryopreservation hub for all European registry donor transplants intended for the Australian-Pacific region. We examined properties of these transplants to ascertain how quality is maintained. METHODS: We analyzed 100 pandemic-related allogeneic mobilized blood-derived stem cell apheresis products generated at 30 collection sites throughout Europe, shipped to and cryopreserved at our center between April and November of 2020. Products were shipped in the cool, subsequently frozen with DMSO as cryoprotectant. Irrespective of origin, all products were frozen within the prescribed shelf-life of 72 h. RESULTS: Prior to cryopreservation, viable stem cell and leukocyte count according to the collection site and our reference laboratory were highly concordant (r(2) = 0.96 and 0.93, respectively) and viability was > 90% in all instances. Median nominal post-thaw recovery of viable CD34+ cells was 42%. Weakly associated with poorer CD34+ cell recovery was higher leukocyte concentration, but not time lag between apheresis or addition of cryopreservant, respectively, and start of freezing. The correlation between pre- and post-thaw CD34+ cell dose was high (r(2) = 0.85), hence predictable. Neutrophil and platelet engraftment were prompt with no evidence of dose dependency within the range of administered cell doses (1.31–15.56 × 10(6) CD34+ cells/kg). CONCLUSIONS: General cryopreservation of allogeneic stem cell transplants is feasible. While more than half of the CD34+ cell content is lost, the remaining stem cells ensure timely engraftment. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12967-021-02810-9. |
format | Online Article Text |
id | pubmed-8027980 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-80279802021-04-08 Allogeneic transplant procurement in the times of COVID-19: Quality report from the central European cryopreservation site Wiercinska, Eliza Schlipfenbacher, Vera Bug, Gesine Bader, Peter Verbeek, Mareike Seifried, Erhard Bonig, Halvard J Transl Med Research BACKGROUND: Because of limitations of transportation imposed by the COVID-19 pandemic, current recommendation calls for cryopreservation of allogeneic stem cell transplants before patient conditioning. A single cell therapy laboratory was selected to function as the central cryopreservation hub for all European registry donor transplants intended for the Australian-Pacific region. We examined properties of these transplants to ascertain how quality is maintained. METHODS: We analyzed 100 pandemic-related allogeneic mobilized blood-derived stem cell apheresis products generated at 30 collection sites throughout Europe, shipped to and cryopreserved at our center between April and November of 2020. Products were shipped in the cool, subsequently frozen with DMSO as cryoprotectant. Irrespective of origin, all products were frozen within the prescribed shelf-life of 72 h. RESULTS: Prior to cryopreservation, viable stem cell and leukocyte count according to the collection site and our reference laboratory were highly concordant (r(2) = 0.96 and 0.93, respectively) and viability was > 90% in all instances. Median nominal post-thaw recovery of viable CD34+ cells was 42%. Weakly associated with poorer CD34+ cell recovery was higher leukocyte concentration, but not time lag between apheresis or addition of cryopreservant, respectively, and start of freezing. The correlation between pre- and post-thaw CD34+ cell dose was high (r(2) = 0.85), hence predictable. Neutrophil and platelet engraftment were prompt with no evidence of dose dependency within the range of administered cell doses (1.31–15.56 × 10(6) CD34+ cells/kg). CONCLUSIONS: General cryopreservation of allogeneic stem cell transplants is feasible. While more than half of the CD34+ cell content is lost, the remaining stem cells ensure timely engraftment. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12967-021-02810-9. BioMed Central 2021-04-08 /pmc/articles/PMC8027980/ /pubmed/33832504 http://dx.doi.org/10.1186/s12967-021-02810-9 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Wiercinska, Eliza Schlipfenbacher, Vera Bug, Gesine Bader, Peter Verbeek, Mareike Seifried, Erhard Bonig, Halvard Allogeneic transplant procurement in the times of COVID-19: Quality report from the central European cryopreservation site |
title | Allogeneic transplant procurement in the times of COVID-19: Quality report from the central European cryopreservation site |
title_full | Allogeneic transplant procurement in the times of COVID-19: Quality report from the central European cryopreservation site |
title_fullStr | Allogeneic transplant procurement in the times of COVID-19: Quality report from the central European cryopreservation site |
title_full_unstemmed | Allogeneic transplant procurement in the times of COVID-19: Quality report from the central European cryopreservation site |
title_short | Allogeneic transplant procurement in the times of COVID-19: Quality report from the central European cryopreservation site |
title_sort | allogeneic transplant procurement in the times of covid-19: quality report from the central european cryopreservation site |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8027980/ https://www.ncbi.nlm.nih.gov/pubmed/33832504 http://dx.doi.org/10.1186/s12967-021-02810-9 |
work_keys_str_mv | AT wiercinskaeliza allogeneictransplantprocurementinthetimesofcovid19qualityreportfromthecentraleuropeancryopreservationsite AT schlipfenbachervera allogeneictransplantprocurementinthetimesofcovid19qualityreportfromthecentraleuropeancryopreservationsite AT buggesine allogeneictransplantprocurementinthetimesofcovid19qualityreportfromthecentraleuropeancryopreservationsite AT baderpeter allogeneictransplantprocurementinthetimesofcovid19qualityreportfromthecentraleuropeancryopreservationsite AT verbeekmareike allogeneictransplantprocurementinthetimesofcovid19qualityreportfromthecentraleuropeancryopreservationsite AT seifriederhard allogeneictransplantprocurementinthetimesofcovid19qualityreportfromthecentraleuropeancryopreservationsite AT bonighalvard allogeneictransplantprocurementinthetimesofcovid19qualityreportfromthecentraleuropeancryopreservationsite |